[Treatment of ornithine transcarbamylase deficiency in a child with glyceryl phenylbutyrate].
苯丁酸甘油酯治疗儿童鸟氨酸氨甲酰基转移酶缺乏症1例.
Child
Glyceryl phenylbutyrate
Hyperammonemia
Ornithine aminotransferase deficiency
Pharmacological monitoring
Urea cycle disorder
Journal
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
ISSN: 1008-8830
Titre abrégé: Zhongguo Dang Dai Er Ke Za Zhi
Pays: China
ID NLM: 100909956
Informations de publication
Date de publication:
15 May 2024
15 May 2024
Historique:
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
27
5
2024
Statut:
ppublish
Résumé
Glyceryl phenylbutyrate (GPB) serves as a long-term management medication for Ornithine transcarbamylase deficiency (OTCD), effectively controlling hyperammonemia, but there is a lack of experience in using this medicine in China. This article retrospectively analyzes the case of a child diagnosed with OTCD at Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, including a review of related literature. After diagnosis, the patient was treated with GPB, followed by efficacy follow-up and pharmacological monitoring. The 6-year and 6-month-old male patient exhibited poor speech development, disobedience, temper tantrums, and aggressive behavior. Blood ammonia levels peaked at 327 μmol/L; urine organic acid analysis indicated elevated uracil levels; cranial MRI showed extensive abnormal signals in both cerebral hemispheres. Genetic testing revealed 苯丁酸甘油酯(glyceryl phenylbutyrate, GPB)是治疗鸟氨酸氨甲酰基转移酶缺乏症(ornithine transcarbamylase deficiency, OTCD)的长期管理药物,可有效控制高氨血症,但国内使用该药的经验匮乏。该文回顾性分析上海交通大学医学院附属上海儿童医学中心1例诊断为OTCD的患儿资料,并进行相关文献复习。该患儿确诊后使用GPB治疗,随后进行疗效随访和药学监测。患儿,男,6岁6个月,语言发育差,不听指令,脾气暴躁并伴有攻击性行为。监测血氨最高327 μmol/L;尿有机酸分析提示尿嘧啶水平升高;头颅磁共振成像示双侧大脑半球广泛异常信号;基因检测发现
Autres résumés
Type: Publisher
(chi)
苯丁酸甘油酯(glyceryl phenylbutyrate, GPB)是治疗鸟氨酸氨甲酰基转移酶缺乏症(ornithine transcarbamylase deficiency, OTCD)的长期管理药物,可有效控制高氨血症,但国内使用该药的经验匮乏。该文回顾性分析上海交通大学医学院附属上海儿童医学中心1例诊断为OTCD的患儿资料,并进行相关文献复习。该患儿确诊后使用GPB治疗,随后进行疗效随访和药学监测。患儿,男,6岁6个月,语言发育差,不听指令,脾气暴躁并伴有攻击性行为。监测血氨最高327 μmol/L;尿有机酸分析提示尿嘧啶水平升高;头颅磁共振成像示双侧大脑半球广泛异常信号;基因检测发现
Identifiants
pubmed: 38802913
pii: 1008-8830(2024)05-0512-06
doi: 10.7499/j.issn.1008-8830.2310050
pii:
doi:
Substances chimiques
Phenylbutyrates
0
glycerol phenylbutyrate
ZH6F1VCV7B
Glycerol
PDC6A3C0OX
Types de publication
Journal Article
Case Reports
Langues
chi
Sous-ensembles de citation
IM
Pagination
512-517Références
Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders[J]. Mol Genet Metab, 2013, 110(1-2): 179- 180.
doi: 10.1016/j.ymgme.2013.07.008
pmcid: PMC4364413
pubmed: 23972786
Matsumoto S, Häberle J, Kido J, et al. Urea cycle disorders: update[J]. J Hum Genet, 2019, 64(9): 833- 847.
doi: 10.1038/s10038-019-0614-4
pubmed: 31110235
Redant S, Empain A, Mugisha A, et al. Management of late onset urea cycle disorders: a remaining challenge for the intensivist?[J]. Ann Intensive Care, 2021, 11(1): 2.
doi: 10.1186/s13613-020-00797-y
pmcid: PMC7788146
pubmed: 33409766
杨臻峥. 用于治疗尿素循环障碍的药物苯丁酸甘油酯[J]. 药学进展, 2013, 37(2): 96- 97.
doi: 10.3969/j.issn.1001-5094.2013.02.013
Yeo M, Rehsi P, Dorman M, et al. Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre[J]. JIMD Rep, 2023, 64(5): 317- 326.
doi: 10.1002/jmd2.12386
pmcid: PMC10494499
pubmed: 37701329
Longo N, Diaz GA, Lichter-Konecki U, et al. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders[J]. Mol Genet Metab, 2021, 132(1): 19- 26.
doi: 10.1016/j.ymgme.2020.12.002
pmcid: PMC8655853
pubmed: 33388234
Martín-Hernández E, Quijada-Fraile P, Correcher P, et al. Switching to glycerol phenylbutyrate in 48 patients with urea cycle disorders: clinical experience in Spain[J]. J Clin Med, 2022, 11(17): 5045.
doi: 10.3390/jcm11175045
pmcid: PMC9457033
pubmed: 36078975
Diaz GA, Schulze A, Longo N, et al. Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients[J]. Mol Genet Metab, 2019, 127(4): 336- 345.
doi: 10.1016/j.ymgme.2019.07.004
pubmed: 31326288
Berry SA, Lichter-Konecki U, Diaz GA, et al. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes[J]. Mol Genet Metab, 2014, 112(1): 17- 24.
doi: 10.1016/j.ymgme.2014.02.007
pmcid: PMC4382922
pubmed: 24630270
Berry SA, Longo N, Diaz GA, et al. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2 months to 2 years[J]. Mol Genet Metab, 2017, 122(3): 46- 53.
doi: 10.1016/j.ymgme.2017.09.002
pubmed: 28916119
中国妇幼保健协会儿童疾病和保健分会遗传代谢学组. 鸟氨酸氨甲酰转移酶缺乏症诊治专家共识[J]. 浙江大学学报(医学版), 2020, 49(5): 539- 547.
doi: 10.3785/j.issn.1008-9292.2020.04.11
pmcid: PMC8800749
pubmed: 33210478
Posset R, Gropman AL, Nagamani SCS, et al. Impact of diagnosis and therapy on cognitive function in urea cycle disorders[J]. Ann Neurol, 2019, 86(1): 116- 128.
doi: 10.1002/ana.25492
pmcid: PMC6692656
pubmed: 31018246
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision[J]. J Inherit Metab Dis, 2019, 42(6): 1192- 1230.
doi: 10.1002/jimd.12100
pubmed: 30982989